Moderna (MRNA) reported 3Q earnings with a miss on both EPS and revenue versus what was expected. Hartaj Singh of Oppenheimer compares Pfizer (PFE) to Moderna. Oppenheimer has a neutral rating on Moderna. He thinks Moderna is a good longer term play.
04 Nov 2021
Market On Close
23 Oct 2022
Morning Trade Live
19 Aug 2022
Market On Close
03 Oct 2022
Futures
04 Nov 2022
Morning Trade Live
31 Aug 2022
Morning Trade Live
11 Aug 2022